<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the efficacy of alpha recombinant human erythropoietin (α-rHuEPO) administered as single agent to 133 patients affected by <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> referring to our Institution in the last 10 years </plain></SENT>
<SENT sid="1" pm="."><plain>WPSS score was "very low" in 67%, "low" in 19%, "intermediate" in 14% </plain></SENT>
<SENT sid="2" pm="."><plain>The starting schedule was: 40,000 IU bi-weekly, with reduction or suspension, when necessary, in responsive patients </plain></SENT>
<SENT sid="3" pm="."><plain>According to new IWG criteria, response rate (RR) was 75%, 66%, 59% after 8, 16, 24 weeks, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Comparing "very low" and "low/intermediate" risk, RR was 81% vs. 43% (P &lt; 0.001); 70% vs. 45% (P = 0.040); 63% vs. 42% (P = NS) after 8, 16, 24 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>RR was significantly influenced by transfusion dependence (P = 0.039) and basal serum EPO level (P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Mean Hb value was 94 ± 11 g/l before therapy; 114 ± 19 after 8 weeks (P &lt; 0.001); 116 ± 18 after 16 weeks (P &lt; 0.001); 114 ± 17 after 24 weeks (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Reduction or suspension of therapy significantly affected Hb level after 4 (P &lt; 0.001) and 8 weeks (P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Conversely, restart of full dosage significantly enhanced again Hb level after 4 (P &lt; 0.01) and 8 weeks (P &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>65% patients are alive (mean survival: 74 weeks) </plain></SENT>
<SENT sid="10" pm="."><plain>Seventy percent are alive in the "very low risk" group and 38% in "low/intermediate risk" group (P &lt; 0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>Overall mean follow-up was 69 weeks (range, 8-376): it was 80 weeks in responsive patients (max 376) and 38 weeks in patients who progressively became unresponsive (max 168) (P &lt; 0.01) </plain></SENT>
<SENT sid="12" pm="."><plain>Median response was 36 weeks, with 33% of patients still responding after one year </plain></SENT>
<SENT sid="13" pm="."><plain>Treatment was well tolerated </plain></SENT>
</text></document>